Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Carisbamate in Partial Epilepsy
NCT00228969Phase 2Completed
- Sponsor
- SK Life Science, Inc.
- Start
- Feb 2005
- Primary completion
- May 2006
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of carisbamate in partial epilepsy (5 arms), sponsored by SK Life Science, Inc. Primary endpoint: Percent reduction in partial-onset seizure frequency at 12 weeks. Started Feb 2005; status: completed.
02
Drugs
carisbamate
03
Conditions
partial epilepsy
Beyond the preview
Go deeper on NCT00228969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00228969.